AUPH Stock — Price, Charts & Analysis

Aurinia Pharmaceuticals Inc. (AUPH) has a trailing P/E of 7.32x and a forward P/E of 15.66x. This places AUPH in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

AUPH trades with 7.32x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether AUPH looks overvalued or undervalued.

AUPH's P/E of 7.32x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

AUPH's trailing EPS is $2.28 and forward EPS is $1.07. Reported earnings growth is 75.50%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Aurinia Pharmaceuticals Inc. generated for each share. AUPH's trailing EPS is $2.28, and investors usually prefer EPS that is positive and growing over time.

Aurinia Pharmaceuticals Inc. has a market cap of $2.22B, making AUPH a mid-cap stock based on the current market value shown on Worldtickers.

AUPH's latest stock price on Worldtickers is $16.70. The latest move is -$0.57 or -3.30%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

AUPH's quote includes a latest price of $16.70. The market open is $17.20. Previous close is $17.27. The intraday range is $16.69 to $17.32.

AUPH is down in the latest quote, with a move of -$0.57 or -3.30%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

AUPH generated $311.51M in trailing revenue. Revenue growth is 18.90%, which helps show whether demand is expanding or slowing.

AUPH's revenue growth is 18.90%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, AUPH shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $314.11M.

Gross margin is 77.88%. Margins show how efficiently Aurinia Pharmaceuticals Inc. turns revenue into profit.

Aurinia Pharmaceuticals Inc. carries $64.14M and holds $443.02M in cash.

AUPH holds $443.02M on its balance sheet.

AUPH's book value per share is $4.63.

Institutions hold 60.39% of AUPH shares. Insiders hold 7.28% of shares. Ownership mix helps investors understand how much of Aurinia Pharmaceuticals Inc. is held by professional investors and company insiders.

AUPH has 133.05M shares outstanding. Float shares are 128.82M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for AUPH, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for AUPH is $1.07. Earnings growth is 75.50%. Revenue growth is 18.90%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

AUPH's trailing EPS is $2.28. Forward EPS is $1.07. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

AUPH is in the Healthcare sector. Its earnings multiple is 7.32x. Its latest displayed growth metric is 18.90%. Compare these figures with sector peers before deciding whether Aurinia Pharmaceuticals Inc. is stronger or weaker than average.

AUPH trades at $16.70. The stock trades at 7.32x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Aurinia Pharmaceuticals Inc.'s fundamentals.

AUPH risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.40, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

AUPH should be compared with companies in Biotechnology. Its earnings multiple is 7.32x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Aurinia Pharmaceuticals Inc. (AUPH) operates in Healthcare, specifically Biotechnology. Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is

AUPH trades on NasdaqGM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

AUPH stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Aurinia Pharmaceuticals Inc.'s official website listed on Worldtickers is www.isotechnika.com/for_investors. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Aurinia Pharmaceuticals Inc. employs about 128 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, AB, Canada. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

AUPH is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

AUPH has traded between $10.34 and $19.25 over the past 52 weeks. At $16.70, it is 13.25% below the high and 61.51% above the low. The 52-week range helps gauge long-term price momentum.

AUPH is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $15.94 and its 200-day moving average is $15.42.

AUPH's RSI is 59.82. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

AUPH's latest RSI reading is 59.82, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for AUPH is near $14.36. Key resistance is near $17.80. Breaks above resistance or below support can change the short-term technical setup.

AUPH's nearest reported support level is $14.36. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

AUPH's nearest reported resistance level is $17.80. A breakout above resistance can improve momentum, especially when volume confirms the move.

AUPH trades about 1.49M shares daily on average. The latest displayed volume is 928.18K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

AUPH's MACD is 0.20, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

AUPH is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 59.82 (neutral). MACD is bullish. Nearest support is around $14.36. Resistance is around $17.80. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $15.48 (7.90% from price). MA50 is $15.94 (4.75% from price). MA200 is $15.42 (8.29% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. AUPH's MA20 is $15.48. MA50 is $15.94. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

AUPH's pivot is near $17.22. Support is near $14.36. Resistance is near $17.80. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for AUPH is near $16.17. These levels help define risk and possible follow-through zones after a breakout or breakdown.

AUPH's Bollinger range is roughly $14.20 to $16.75. Band width is near 16.48%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

AUPH's ATR-based typical daily range is about 3.92%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 928.18K shares. Average volume is about 1.49M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

AUPH's all-time high shown on Worldtickers is $33.97. Its all-time low is $1.41. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

AUPH has a beta of 1.40, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.